Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report

INTRODUCTION: Gefitinib is a new molecular-targeted agent for the treatment of patients with advanced non-small cell lung cancer that fail to respond to conventional chemotherapy. Gefitinib is considered to be well tolerated and less toxic compared with conventional cytotoxic drugs. However, interst...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamochi, Kazuya, Suzuki, Kazuya, Bashar, Abul Hasan Muhammad, Yajima, Kiyoshige, Mochizuki, Takahiro, Itaya, Toru, Funai, Kazuhito
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194710/
https://www.ncbi.nlm.nih.gov/pubmed/18021415
http://dx.doi.org/10.1186/1752-1947-1-138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194710/
https://www.ncbi.nlm.nih.gov/pubmed/18021415
http://dx.doi.org/10.1186/1752-1947-1-138

Ejemplares similares